<DOC>
	<DOC>NCT02101554</DOC>
	<brief_summary>Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of morphine sulfate with a sequestered naltrexone core in children 7-17 with moderate-severe pain.</brief_summary>
	<brief_title>Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain</brief_title>
	<detailed_description>Subjects, once stabilized to Embeda, need only complete a minimum of 2 of the 6 week study duration to satisfy the PK endpoint. A safety follow-up visit is required at 1 week post-last dose.</detailed_description>
	<criteria>Children 717 with moderate to severe pain requiring around the clock treatment with an opioid analgesic. Be an experienced opioid user, defined as any subject treated with opioid therapy, equivalent or equal to &gt;20 mg per day of morphine, for a period of 3 consecutive days immediately prior to first day of dosing. ColumbiaSuicide Severity Rating Scale (CSSRS) for suicidal ideation and behavior in past year. Hypersensitivity to morphine, naltrexone. A life expectancy (assessed by investigator) of less than 6 months or is no longer capable of taking medication orally. Undergone surgery within 3 days prior to the first day of dosing.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>pain indication</keyword>
	<keyword>controlled release morphine</keyword>
</DOC>